These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 9773094)
41. Halting osteoarthritis progression. Bone underneath cartilage exacerbates OA damage via surplus bone formation. Duke Med Health News; 2013 Aug; 19(8):5-6. PubMed ID: 23984453 [No Abstract] [Full Text] [Related]
42. How can one develop disease-modifying drugs in osteoarthritis? Dougados M Curr Rheumatol Rep; 2005 Mar; 7(1):22-8. PubMed ID: 15760577 [TBL] [Abstract][Full Text] [Related]
44. [Scleromyxedema: a new therapeutic proposal]. Puiatti P; Goitre M G Ital Dermatol Venereol; 1986; 121(3):223-7. PubMed ID: 3017848 [No Abstract] [Full Text] [Related]
45. [Osteological aspects]. Lange U Z Rheumatol; 2014 May; 73(4):315. PubMed ID: 24811355 [No Abstract] [Full Text] [Related]
46. [Piascledine in the treatment of parodontopathies]. Jarzab G Czas Stomatol; 1975 Apr; 28(4):443-5. PubMed ID: 1055040 [No Abstract] [Full Text] [Related]
47. [Clinical study on the effectiveness of Insadol]. Marxer MA; Studer-Stäheli C SSO Schweiz Monatsschr Zahnheilkd; 1978 May; 88(5):582-91. PubMed ID: 349689 [TBL] [Abstract][Full Text] [Related]
48. The so-called findings of healing in arthropathia deformans. Thurner J; De Los Santos E Philipp J Surg Surg Spec; 1965; 20(2):79-90. PubMed ID: 5896929 [No Abstract] [Full Text] [Related]
49. The role of bone in osteoarthritis. Proceedings of the 2001 Coral Gables Symposium. Osteoarthritis Cartilage; 2004; 12 Suppl A():S1-76. PubMed ID: 14698634 [No Abstract] [Full Text] [Related]
51. Metformin as a potential disease-modifying agent in osteoarthritis: the present and the future. Sit RWS Osteoarthritis Cartilage; 2022 Nov; 30(11):1418-1419. PubMed ID: 36030060 [No Abstract] [Full Text] [Related]
52. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Manicourt DH; Altman RD; Williams JM; Devogelaer JP; Druetz-Van Egeren A; Lenz ME; Pietryla D; Thonar EJ Arthritis Rheum; 1999 Jun; 42(6):1159-67. PubMed ID: 10366108 [TBL] [Abstract][Full Text] [Related]
53. [Do 'chondroprotective agents' agents exist in osteoarthritis? Required proof]. Lequesne M; Cadet C Therapie; 1998; 53(1):7-16. PubMed ID: 9773094 [TBL] [Abstract][Full Text] [Related]
54. Subchondral bone in osteoarthritis physiopathology: state-of-the art and perspectives. Henrotin Y; Pesesse L; Sanchez C Biomed Mater Eng; 2009; 19(4-5):311-6. PubMed ID: 20042798 [TBL] [Abstract][Full Text] [Related]
55. Rationale for the potential use of calcitonin in osteoarthritis. Manicourt DH; Devogelaer JP; Azria M; Silverman S J Musculoskelet Neuronal Interact; 2005; 5(3):285-93. PubMed ID: 16172519 [TBL] [Abstract][Full Text] [Related]
56. Guidelines for testing slow acting drugs in osteoarthritis. Lequesne M; Brandt K; Bellamy N; Moskowitz R; Menkes CJ; Pelletier JP; Altman R J Rheumatol Suppl; 1994 Sep; 41():65-71; discussion 72-3. PubMed ID: 7799389 [TBL] [Abstract][Full Text] [Related]